ClinicalTrials.gg
CompletedNCT01453569Updated Jan 27, 2015Results posted

Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease

A Phase 2 interventional study of Sodium oligo-mannurarate 600mg and Sodium oligo-mannurarate 900mg in Alzheimer Disease and Cognitive Impairment, sponsored by Shanghai Greenvalley Pharmaceutical Co., Ltd.. Completed at 24 sites in China. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2015-01-27.

Sponsored by Shanghai Greenvalley Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 260 studies in Alzheimer Disease with a site in China — 150 open to participants now, 162 under way, 21 of them phase 3. Alzheimer Disease · China.

Enrollment
44th of 176
255 · median 100
Started
2011
with 3 others
Phase 2
20 of 260
7 open now
Registered
10th of 260
by date

Among the 260 studies in Alzheimer Disease with a site in China, this one is the 44th largest by enrollment of the 176 interventional ones that give a count, is one of 4 that started in 2011, is one of 20 in phase 2, and was the 10th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

150 of the 260 studies in Alzheimer Disease with a site in China are open now. Recruiting first, the newest first:

145 more — sign in →

All 150 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 260 studies in Alzheimer Disease with a site in China, or all of them as a file.
02

Study summary

The primary purpose of this study is to determine whether sodium oligo-mannurarate capsule is effective and safe in the treatment of mild to moderate alzheimer' disease, and to determine the best therapeutic dose of sodium oligo-mannurarate capsule.

Read the detailed description

Alzheimer's disease is known for placing a great burden on caregivers which includes social, psychological, physical or economic aspects. Research indicates that the disease is associated with plaques and tangles in the brain. Currently used treatments offer a small symptomatic benefit. No treatments to delay or halt the progression of the disease are, as of yet, available. The investigators suppose sodium oligo-mannurarate capsule to be effective to halt the progression of the disease.

03

Conditions studied

  • Alzheimer Disease
  • Cognitive Impairment
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least primarily educated.
  • Accord with Probable Alzheimer disease of National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association(NINCDS-ADRDA)'s Criteria.
  • 10 points ≤ Minimum Mean-Square Error() ≤ 24 points.
  • Hachinski ischemia scale \<4 points.
  • Hamilton depression scale ≤10 points.
  • Should have stable accompanying person, or at least contact 2 hours per day, 4 days per week with accompanying person. The accompanying person should help the patient throughout the trial.
  • Signed the information consent form.

Exclusion criteria

Exclusion Criteria:

  • Have been in other clinical trials within 30 days before this trial' start.
  • women during pregnancy or lactation.
  • Dementia caused by other diseases.
  • previous nervous system diseases.
  • Abnormal laboratory results.
  • Uncontrolled hypertension.
  • Unstable or serious diseases of heart, lung, liver, kidney and blood.
  • Visual or auditory handicap.
  • Significant focal lesions revealed by electronic computer X-ray tomography(CT) or magnetic resonance imaging(MRI) in one year before enrollment.
  • Alcohol abuse or drug abuse.
  • psychotic, including patients with serious depression.
  • Patients being in drug therapy of Alzheimer disease which cannot be stopped.
  • In treatment of heparin, Polysaccharide sulfate, mannose ester 3 weeks before the recruitment.
  • Investigator consider the patient cannot finish this trial for any reason.
  • Relatives or employees of the investigators, staff of the investigate centers, contract research organization and sponsor.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
255 participants (actual)

Study arms

  • Experimental
    sodium oligo-mannurarate 900mg

    Drug: Sodium oligo-mannurarate 900mg

  • Experimental
    sodium oligo-mannurarate 600mg

    Drug: Sodium oligo-mannurarate 600mg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugSodium oligo-mannurarate 600mg

    sodium oligo-mannurarate capsule 600mg twice a day for 24 weeks

    Also known as: Sodium oligo-mannurarate low dose

  • DrugSodium oligo-mannurarate 900mg

    sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks

    Also known as: Sodium oligo-mannurarate high dose

  • DrugPlacebo

    simulant of sodium oligo-mannurarate capsule

06

What researchers measure

Primary outcomes

  1. Change of Alzheimer's Disease Assessment Scale-cognitive Subscale(ADAS-cog)/12 After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule

    Alzheimer's Disease Assessment Scale-cognitive Subscale(ADAS-cog)/12 is the most popular cognitive testing instrument used in clinical trials. It consists of 12 tasks measuring the disturbances of memory, language, praxis, attention and other cognitive abilities which are often referred to as the core symptoms of AD. The total score ranges 0-75, the higher score indicates more severity of the disease. Change after 24 wks treatment was calculated by the week 24 minus week 0 (baseline), and a negative change represents an improvement.

    Time frame: 24 weeks

Secondary outcomes

  1. Change of Clinician's Interview-Based Impression of Change Plus(CIBIC-plus) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule

    Clinician's Interview-Based Impression of Change Plus(CIBIC-plus) is widely used in antidementia drug trials. It comprises Likert scales for disease severity and changes, and written accounts summarizing semistructured interviews evaluating behavior, cognition, and function. The results classified as 7 degrades as: Markedly improved, Moderately improved, Minimally improved, No change, Minimally worse, Moderately worse, and Markedly worse.

    Time frame: 24 weeks

  2. Change of Alzheimer's Disease Cooperative Study/Activities of Daily(ADCS-ADL) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule

    Alzheimer's Disease Cooperative Study/Activities of Daily (ADCS-ADL) is a scale assessed the daily activties of AD patients after interviewed the caregiver. The scale mainly assess the eating, walking, writing, bathing and reading, et al of the subject. The total score ranges 0-78, the higher score indicate improvement in daily activities. Change after 24 wks treatment was calculated by the week 24 minus week 0 (baseline), and a positive change represents an improvement.

    Time frame: 24 weeks

  3. Change of Neuropsychiatric Inventory(NPI) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule

    Neuropsychiatric Inventory (NPI) is a scale to obtain information on the presence of psychopathology in patient with brain disorders. The NPI was developed for application to patients with AD and other dementias, but it may be useful in the assessment of behavioral changes in other conditions. Twelve behavioral areas included in the NPI will be assessed in this trial: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety and elation/euphoria, et al. The total score ranges 0 to 120, the higher score indicates worse state of the AD patient. Change after 24wks treatmnt was calculated by the week 24 minus week 0 (baseline), and a negative change represents an improvement.

    Time frame: 24 weeks

07

Results

Posted Jan 27, 2015

Participant flow

Participant flow — Overall Study
MilestoneSodium Oligo-mannurarate 900mgSodium Oligo-mannurarate 600mgPlacebo
Started868485
Completed757078
Not completed11147

Outcome measures

PrimaryChange of Alzheimer's Disease Assessment Scale-cognitive Subscale(ADAS-cog)/12 After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule

Alzheimer's Disease Assessment Scale-cognitive Subscale(ADAS-cog)/12 is the most popular cognitive testing instrument used in clinical trials. It consists of 12 tasks measuring the disturbances of memory, language, praxis, attention and other cognitive abilities which are often referred to as the core symptoms of AD. The total score ranges 0-75, the higher score indicates more severity of the disease. Change after 24 wks treatment was calculated by the week 24 minus week 0 (baseline), and a negative change represents an improvement.

Time frame:
24 weeks
Reported as:
Mean · units on a scale
Change of Alzheimer's Disease Assessment Scale-cognitive Subscale(ADAS-cog)/12 After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule
units on a scaleSodium Oligo-mannurarate 900mgSodium Oligo-mannurarate 600mgPlacebo
Change of Alzheimer's Disease Assessment Scale-cognitive Subscale(ADAS-cog)/12 After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule-2.58 ± 0.62-1.39 ± 0.75-1.45 ± 0.77
SecondaryChange of Clinician's Interview-Based Impression of Change Plus(CIBIC-plus) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule

Clinician's Interview-Based Impression of Change Plus(CIBIC-plus) is widely used in antidementia drug trials. It comprises Likert scales for disease severity and changes, and written accounts summarizing semistructured interviews evaluating behavior, cognition, and function. The results classified as 7 degrades as: Markedly improved, Moderately improved, Minimally improved, No change, Minimally worse, Moderately worse, and Markedly worse.

Time frame:
24 weeks
Reported as:
Number · participants
Change of Clinician's Interview-Based Impression of Change Plus(CIBIC-plus) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule
participantsSodium Oligo-mannurarate 900mgSodium Oligo-mannurarate 600mgPlacebo
Markedly improved023
Moderately improved1396
Minimally improved291832
No change352325
Minimally worse42117
Moderately worse230
Markedly worse000
SecondaryChange of Alzheimer's Disease Cooperative Study/Activities of Daily(ADCS-ADL) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule

Alzheimer's Disease Cooperative Study/Activities of Daily (ADCS-ADL) is a scale assessed the daily activties of AD patients after interviewed the caregiver. The scale mainly assess the eating, walking, writing, bathing and reading, et al of the subject. The total score ranges 0-78, the higher score indicate improvement in daily activities. Change after 24 wks treatment was calculated by the week 24 minus week 0 (baseline), and a positive change represents an improvement.

Time frame:
24 weeks
Reported as:
Mean · units on a scale
Change of Alzheimer's Disease Cooperative Study/Activities of Daily(ADCS-ADL) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule
units on a scaleSodium Oligo-mannurarate 900mgSodium Oligo-mannurarate 600mgPlacebo
Change of Alzheimer's Disease Cooperative Study/Activities of Daily(ADCS-ADL) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule-0.49 ± 0.91-0.47 ± 0.88-1.06 ± 0.85
SecondaryChange of Neuropsychiatric Inventory(NPI) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule

Neuropsychiatric Inventory (NPI) is a scale to obtain information on the presence of psychopathology in patient with brain disorders. The NPI was developed for application to patients with AD and other dementias, but it may be useful in the assessment of behavioral changes in other conditions. Twelve behavioral areas included in the NPI will be assessed in this trial: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety and elation/euphoria, et al. The total score ranges 0 to 120, the higher score indicates worse state of the AD patient. Change after 24wks treatmnt was calculated by the week 24 minus week 0 (baseline), and a negative change represents an improvement.

Time frame:
24 weeks
Reported as:
Mean · units on a scale
Change of Neuropsychiatric Inventory(NPI) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule
units on a scaleSodium Oligo-mannurarate 900mgSodium Oligo-mannurarate 600mgPlacebo
Change of Neuropsychiatric Inventory(NPI) After 24 Wks Treatment of Sodium Oligo-mannurarate Capsule-1.11 ± 1.220.24 ± 0.83-2.08 ± 0.98

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sodium Oligo-mannurarate 900mg—3/86 (3.5%)3/86 (3.5%)
Sodium Oligo-mannurarate 600mg—6/84 (7.1%)12/84 (14.3%)
Placebo—6/85 (7.1%)5/85 (5.9%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventSodium Oligo-mannurarate 900mgSodium Oligo-mannurarate 600mgPlacebo
Behavioral and psychiatric symptomsPsychiatric disorders0/861/840/85
Subdural hematomaVascular disorders0/861/840/85
Implantation of artificial heart pacemakerCardiac disorders0/861/840/85
HerniaGeneral disorders0/861/840/85
Compressive fracture of vertebraMusculoskeletal and connective tissue disorders0/861/840/85
Lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/861/840/85
OsteoarthritisMusculoskeletal and connective tissue disorders0/860/841/85
StrokeNervous system disorders0/860/841/85
Paralysis of oculomotor nerveNervous system disorders0/860/841/85
AppendicitisGastrointestinal disorders0/860/841/85
Most frequent other events
Most frequent other events
EventSodium Oligo-mannurarate 900mgSodium Oligo-mannurarate 600mgPlacebo
Psychiatiric disordersPsychiatric disorders0/865/840/85
GastrointestinalGastrointestinal disorders1/860/844/85
DermatologicSkin and subcutaneous tissue disorders1/862/840/85
Ear and labyrinthEar and labyrinth disorders0/861/841/85
Injuries, toxicosis, complications due to surgeryInjury, poisoning and procedural complications0/861/840/85
Muscular and connective tissueMusculoskeletal and connective tissue disorders0/861/840/85
CNS disordersNervous system disorders0/861/840/85
Respiratoty system, chest and mediastinumRespiratory, thoracic and mediastinal disorders0/861/840/85
Reproductive system and mammary glandReproductive system and breast disorders1/860/840/85

Baseline characteristics

All the treated subjects were evaluated for safety. 2, 8 and 3 subjects were excluded from FAS in placebo, 600 mg and 900 mg group respectively. So the case No. were 83, 76, 83 for placebo, 600 mg and 900 mg group respectively.

Age, Continuous
Age, Continuous(years)Sodium Oligo-mannurarate 900mgSodium Oligo-mannurarate 600mgPlaceboTotal
Mean70.39 ± 8.5170.26 ± 8.4070.34 ± 8.1370.33 ± 8.24
Sex: Female, Male
Sex: Female, Male(Participants)Sodium Oligo-mannurarate 900mgSodium Oligo-mannurarate 600mgPlaceboTotal
Female504152143
Male33353199
08

Study locations

24 sites
  • Beijing Hospital
    Beijing, Beijing 100005, China
  • Chongqing Medical University Second Affiliated Hospital
    Chongqing, Chongqing 400010, China
  • The First Affliated Hospital of Third Military Medical University
    Chongqing, Chongqing 400038, China
  • The Third Affliated Hospital of Third Military Medical University
    Chongqing, Chongqing 400042, China
  • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
    Guangzhou, Guangdong 510120, China
  • Guangzhou Brain Hospital
    Guangzho, Guangdong 510170, China
  • The 251 Hospital of People's Liberation Army
    Zhangjiakou, Hebei 075000, China
  • The First Affliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
  • Wuhan General Hospital of Guangzhou Military of People's Military Army
    Wuhan, Hubei 430070, China
  • Zhongnan Hospital of Wuhan University
    Wuhan, Hubei 430077, China
  • Hunan Provincial People's Hospital
    Changsha, Hunan 410005, China
  • The Central Hospital of Baotou
    Baotou, Inner Mongolia 014040, China
  • The Affliated Brain Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210029, China
  • Wuxi Mental Health Center
    Wuxi, Jiangsu 214151, China
  • The First Affliated Hospital of Chinese Medical University
    Shenyang, Liaoning 110001, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250012, China
  • Shandong Provincial Hospital
    Jinan, Shandong 250021, China
  • The Second Hospital of Shandong University
    Jinan, Shandong 250033, China
  • The Ninth Hospital, Shanghai Jiao Tong University school of Medicine
    Shanghai, Shanghai 200011, China
  • Shanghai Mental Health Center , Shanghai Jiao Tong University school of Medicine
    Shanghai, Shanghai 200030, China
  • Tangdu Hospital of The Forth Military Medical University of PLA
    Xi'an, Shanxi 710038, China
  • West China Hospital, West China School of Medicine Sichuan University
    Chengdu, Sichuan 610041, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin 300052, China
  • Sir Run Run Shaw Hospital, Medical college of Zhejiang University
    Hangzhou, Zhejiang 310016, China
09

References and documents

Publications

  • Wang T, Kuang W, Chen W, Xu W, Zhang L, Li Y, Li H, Peng Y, Chen Y, Wang B, Xiao J, Li H, Yan C, Du Y, Tang M, He Z, Chen H, Li W, Lin H, Shi S, Bi J, Zhou H, Cheng Y, Gao X, Guan Y, Huang Q, Chen K, Xin X, Ding J, Geng M, Xiao S. A phase II randomized trial of sodium oligomannate in Alzheimer's dementia. Alzheimers Res Ther. 2020 Sep 14;12(1):110. doi: 10.1186/s13195-020-00678-3. PubMed 32928279 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2011
First posted
Oct 18, 2011
Start
Oct 2011
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Results first posted
Jan 27, 2015
Last update
Jan 27, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01453569
Lead sponsor
Shanghai Greenvalley Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Oct 18, 2011
Start date
Oct 2011
Primary completion
Aug 2013
Completion
Aug 2013
Results posted
Jan 27, 2015
Last update
Jan 27, 2015

Study contacts

Shifu Xiao, M.D.
principal investigator · Shanghai Mental Health Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion